Compositions and methods for treating IgE-mediated disorders

• US 9,062,117 B2
• Filed: 03/04/2013
• Issued: 06/23/2015
• Est. Priority Date: 09/17/2008
• Status: Active Grant

• Current Assignee: Xencor, Inc.
• Original Assignee: Xencor, Inc.
• Inventors: Desjarlais, John, Chu, Seung Y., Horton, Holly M., Bernett, Matthew J.
• Primary Examiner(s): SZPERKA, MICHAEL EDWARD
• Application Number:
  US13/784,649
• Publication Number:
  US 20130177553A1
• Time in Patent Office: 841 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C07K 16/4291 against IgE
• CPC Class Codes: C07K 16/464 Igs containing CDR-residues from one specie grafted between FR-residues from another
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.

Claims

1. A method of treating allergic asthma in a patient comprising administering to said patient an anti-IgE antibody comprising:

a heavy chain variable region having SEQ ID NO;

17 and a light chain variable region having SEQ ID NO;

21.

2. The method of claim 1, wherein the antibody comprises a heavy chain having SEQ ID NO:

41 and a light chain having SEQ ID NO;

40.